Rachel M Wake1,2, Nelesh P Govender1,3,4, Tanvier Omar5,6, Carolina Nel5,6, Ahmad Haeri Mazanderani7,8, Aaron S Karat9, Nazir A Ismail10, Caroline T Tiemessen7,11, Joseph N Jarvis12,13,14, Thomas S Harrison2. 1. Centre for Healthcare-associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, Johannesburg, South Africa. 2. Institute of Infection & Immunity, St George's University of London, United Kingdom. 3. School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. 4. Division of Medical Microbiology, University of Cape Town, South Africa. 5. Department of Anatomical Pathology, University of the Witwatersrand, South Africa. 6. Department of Pathology, National Health Laboratory Services, South Africa. 7. Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. 8. Department of Medical Virology, University of Pretoria, South Africa. 9. Tuberculosis Centre, London School of Hygiene & Tropical Medicine, United Kingdom. 10. Centre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa. 11. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 12. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom. 13. Botswana-UPenn Partnership, Gaborone. 14. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: Cryptococcal antigen (CrAg) screening and treatment with preemptive fluconazole reduces the incidence of clinically evident cryptococcal meningitis in individuals living with advanced human immunodeficiency virus (HIV) disease. However, mortality remains higher in CrAg-positive than in CrAg-negative patients with similar CD4+ T-lymphocyte counts. METHODS: We conducted a cohort study to investigate causes of morbidity and mortality during 6 months of follow-up among asymptomatic CrAg-positive and CrAg-negative (ratio of 1:2) patients living with HIV with CD4 counts <100 cells/µL attending 2 hospitals in Johannesburg, South Africa. When possible, minimally invasive autopsy (MIA) was performed on participants who died. RESULTS: Sixty-seven CrAg-positive and 134 CrAg-negative patients were enrolled. Death occurred in 17/67 (25%) CrAg-positive and 12/134 (9%) CrAg-negative participants (hazard ratio for death, adjusted for CD4 count, 3.0; 95% confidence interval, 1.4-6.7; P = .006). Cryptococcal disease was an immediate or contributing cause of death in 12/17 (71%) CrAg-positive participants. Postmortem cryptococcal meningitis and pulmonary cryptococcosis were identified at MIA in all 4 CrAg-positive participants, 3 of whom had negative cerebrospinal fluid CrAg tests from lumbar punctures (LPs) at the time of CrAg screening. CONCLUSIONS: Cryptococcal disease was an important cause of mortality among asymptomatic CrAg-positive participants despite LPs to identify and treat those with subclinical cryptococcal meningitis and preemptive fluconazole for those without meningitis. Thorough investigation for cryptococcal disease with LPs and blood cultures, prompt ART initiation, and more intensive antifungals may reduce mortality among asymptomatic CrAg-positive patients identified through screening.
BACKGROUND: Cryptococcal antigen (CrAg) screening and treatment with preemptive fluconazole reduces the incidence of clinically evident cryptococcal meningitis in individuals living with advanced human immunodeficiency virus (HIV) disease. However, mortality remains higher in CrAg-positive than in CrAg-negative patients with similar CD4+ T-lymphocyte counts. METHODS: We conducted a cohort study to investigate causes of morbidity and mortality during 6 months of follow-up among asymptomatic CrAg-positive and CrAg-negative (ratio of 1:2) patients living with HIV with CD4 counts <100 cells/µL attending 2 hospitals in Johannesburg, South Africa. When possible, minimally invasive autopsy (MIA) was performed on participants who died. RESULTS: Sixty-seven CrAg-positive and 134 CrAg-negative patients were enrolled. Death occurred in 17/67 (25%) CrAg-positive and 12/134 (9%) CrAg-negative participants (hazard ratio for death, adjusted for CD4 count, 3.0; 95% confidence interval, 1.4-6.7; P = .006). Cryptococcal disease was an immediate or contributing cause of death in 12/17 (71%) CrAg-positive participants. Postmortem cryptococcal meningitis and pulmonary cryptococcosis were identified at MIA in all 4 CrAg-positive participants, 3 of whom had negative cerebrospinal fluid CrAg tests from lumbar punctures (LPs) at the time of CrAg screening. CONCLUSIONS:Cryptococcal disease was an important cause of mortality among asymptomatic CrAg-positive participants despite LPs to identify and treat those with subclinical cryptococcal meningitis and preemptive fluconazole for those without meningitis. Thorough investigation for cryptococcal disease with LPs and blood cultures, prompt ART initiation, and more intensive antifungals may reduce mortality among asymptomatic CrAg-positive patients identified through screening.
Authors: Ilesh V Jani; Nádia E Sitoe; Eunice R Alfai; Patrina L Chongo; Jorge I Quevedo; Beatriz M Rocha; Jonathan D Lehe; Trevor F Peter Journal: Lancet Date: 2011-09-25 Impact factor: 79.321
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Rachel M Wake; Joseph N Jarvis; Thomas S Harrison; Nelesh P Govender Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.731
Authors: A-C L Meyer; C K Kendi; J A Penner; N Odhiambo; B Otieno; E Omondi; E Opiyo; E A Bukusi; C R Cohen Journal: Trop Med Int Health Date: 2013-02-01 Impact factor: 2.622
Authors: Elvis Temfack; Charles Kouanfack; Leonella Mossiang; Angela Loyse; Marie C Fonkoua; Síle F Molloy; Sinata Koulla-Shiro; Eric Delaporte; Françoise Dromer; Thomas Harrison; Olivier Lortholary Journal: Front Microbiol Date: 2018-03-13 Impact factor: 5.640
Authors: Emily B Wong; Tanvier Omar; Gosetsemang J Setlhako; Regina Osih; Charles Feldman; David M Murdoch; Neil A Martinson; David R Bangsberg; W D F Venter Journal: PLoS One Date: 2012-10-16 Impact factor: 3.240
Authors: Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass Journal: Open Forum Infect Dis Date: 2015-04-02 Impact factor: 3.835
Authors: Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Rachel M Wake; Nazir A Ismail; Shaheed V Omar; Farzana Ismail; Caroline T Tiemessen; Thomas S Harrison; Joseph N Jarvis; Nelesh P Govender Journal: Open Forum Infect Dis Date: 2022-04-17 Impact factor: 4.423
Authors: William J Hurt; Mark W Tenforde; Mooketsi Molefi; Hannah K Mitchell; Thandi Milton; Martin S Azama; Irene Goercke; Fredah Mulenga; Nametso Tlhako; Katlego Tsholo; Tuhina Srivastava; Tshepo B Leeme; Godfrey Simoonga; Charles Muthoga; Kwana Lechiile; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2021-05-18 Impact factor: 9.079
Authors: Shichina Kannambath; Joseph N Jarvis; Rachel M Wake; Nicky Longley; Angela Loyse; Vicky Matzaraki; Raúl Aguirre-Gamboa; Cisca Wijmenga; Ronan Doyle; Maria Paximadis; Caroline T Tiemessen; Vinod Kumar; Alan Pittman; Graeme Meintjes; Thomas S Harrison; Mihai G Netea; Tihana Bicanic Journal: Open Forum Infect Dis Date: 2020-10-16 Impact factor: 3.835
Authors: Supavit Chesdachai; Nicole W Engen; Joshua Rhein; Lillian Tugume; Tadeo Kiiza Kandole; Mahsa Abassi; Kenneth Ssebambulidde; John Kasibante; Darlisha A Williams; Caleb P Skipper; Kathy H Hullsiek; Abdu K Musubire; Radha Rajasingham; David B Meya; David R Boulware Journal: Open Forum Infect Dis Date: 2020-10-29 Impact factor: 3.835
Authors: Nelesh P Govender; Graeme Meintjes; Phetho Mangena; Jeremy Nel; Samantha Potgieter; Denasha Reddy; Helena Rabie; Douglas Wilson; John Black; David Boulware; Tom Boyles; Tom Chiller; Halima Dawood; Sipho Dlamini; Thomas S Harrison; Prudence Ive; Joseph Jarvis; Alan Karstaedt; Matamela C Madua; Colin Menezes; Mahomed-Yunus S Moosa; Zaaheera Motlekar; Amir Shroufi; Sarah Lynn Stacey; Merika Tsitsi; Gilles van Cutsem; Ebrahim Variava; Michelle Venter; Rachel Wake Journal: South Afr J HIV Med Date: 2019-11-08 Impact factor: 2.744